Mesoblast Limited (MESO) Actualités

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first...

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...